I agree to inform any patients, or any persons used as controls, that the drugs are being used for investigational purposes and I will ensure that the requirements relating to obtaining informed consent in 21 CFR Part 50 and institutional review board (IRB) review and approval in 21 CFR Part 56 are met. I agree to report to the sponsor adverse experiences that occur in the course of the investigation(s) in accordance with 21 CFR 312.64. I have read and understand the information in the investi.
Open form follow the instructions
Easily sign the form with your finger
Send filled & signed form or save
How to fill out the FDA 1572 online
The FDA 1572 form, also known as the Statement of Investigator, is a crucial document required for clinical investigations of new drugs. This guide will provide detailed instructions on how to complete the form online, ensuring that you fulfill all necessary requirements.
Follow the steps to complete the FDA 1572 form effectively.
- Click ‘Get Form’ button to obtain the form and open it for completing your information.
- Enter your full name and address in the designated fields under the 'Name and address of investigator' section. Ensure that you include the city, state, country, and postal code.
- In the section for education, training, and experience, select either 'Curriculum Vitae' or 'Other Statement of Qualifications' to demonstrate your expertise related to the clinical investigation.
- Provide the name and address of any medical school, hospital, or research facility where the clinical investigations will be conducted, ensuring all fields are accurately filled.
- List the name and address of any clinical laboratory facilities you will utilize during the study. Include the complete address for clarity.
- Identify the Institutional Review Board (IRB) that is responsible for the study. Fill in their name and complete address details.
- If applicable, list the names of subinvestigators. If not applicable, you may state 'None'.
- Provide the name and code number of the protocol(s) in the Investigational New Drug (IND) application related to the investigation.
- Select the appropriate clinical protocol information for your investigation phase, either providing a general outline for Phase 1 or detailed protocol for Phase 2 or 3.
- Acknowledge your commitments by reading and agreeing to the outlined responsibilities. Ensure you sign and date the form at the bottom.
- Once completed, save your changes. You can choose to download, print, or share the form as needed.
Begin filling out your FDA 1572 form online today to ensure compliance and completeness.
Experience a faster way to fill out and sign forms on the web. Access the most extensive library of templates available.
Related content
INVESTIGATORS. SHOULD NOT SEND THIS FORM DIRECTLY TO THE FOOD AND DRUG ADMINISTRATION...
What is the Statement of Investigator, Form FDA 1572? The Statement of Investigator, Form...
Failure to comply with Form FDA 1572 requirements. • Inadequate subject protection;...
Get answers to your most pressing questions about US Legal Forms API.
Does the 1572 need to be submitted to the FDA?
Yes, the FDA 1572 must be submitted to the FDA as part of the clinical research process. This submission enables the FDA to monitor compliance and the integrity of the ongoing trial. By providing this information, you contribute to a systematic approach to clinical research that prioritizes safety and adherence to regulations.
Which of the following reports must be filed using a form FDA 1572?
The reports that must use form FDA 1572 include those related to adverse events and changes in the study team. These reports help ensure that the FDA and stakeholders are informed about developments in the clinical trial. Always check for any specific requirements from the FDA to ensure full compliance.
What reports must be filed using a form FDA 1572?
Various reports must reference or incorporate the FDA 1572, primarily concerning safety and trial changes. This includes adverse event reports, as well as updates on investigator qualifications. Compliance with these reporting requirements is crucial to ensure the ongoing safety and efficacy of the clinical trial.
When should a form 1572 be modified?
Form FDA 1572 should be modified when there are changes in the study team or significant updates regarding the trial site. For instance, if a new investigator or sub-investigator joins the study, an updated form is necessary. Keeping the form current helps maintain compliance and transparency throughout the trial.
What is an FDA Form 1572 purpose and use?
The FDA Form 1572 serves as a declaration of compliance by the principal investigator for a clinical study. Its purpose is to outline the investigator's responsibilities and to provide essential details about the trial site. This form ensures that studies adhere to FDA regulations, enhancing the integrity and safety of clinical research.
What documentation must accompany the form 1572 submission?
When submitting form FDA 1572, certain documentation must accompany it. This includes a curriculum vitae or resume of the principal investigator, as well as information about any sub-investigators involved in the trial. Submitting this information helps the FDA assess the qualifications of those managing the clinical trial.
Who completes form FDA 1572?
The principal investigator of a clinical trial is responsible for completing the FDA 1572. This individual is typically a qualified physician who oversees the study and ensures compliance with applicable regulations. By signing the form, the investigator affirms their commitment to the trial and their ability to fulfill its obligations.
What does the form FDA 1572 record the investigator's commitment to abide by?
The FDA 1572 records the investigator's commitment to adhere to all regulations set forth by the FDA regarding clinical trials. It details their responsibilities, the protocol of the trial, and the reporting of adverse events. Therefore, this form is crucial for maintaining the integrity of the clinical trial process. Understanding this commitment helps investigators ensure that they are following best practices.
Which party is responsible for reporting directly to the FDA the investigators' financial interests with the sponsor?
It is the responsibility of the sponsor to report directly to the FDA any financial interests that investigators may have with them. This transparency ensures that potential conflicts of interest are disclosed upfront, fostering trust in the clinical trial process. Knowing this responsibility is vital for sponsors and investigators alike. By managing financial disclosures, both parties can maintain compliance with FDA regulations.
What is the equivalent of FDA 1572 in Europe?
The equivalent of the FDA 1572 in Europe is the Clinical Trial Application (CTA), which is submitted to the respective regulatory authority in European countries. The CTA outlines the details of the clinical trial, similar to what the FDA 1572 does in the United States. Understanding this equivalency is essential for international investigators aiming to navigate both regulatory systems effectively. Essentially, if you're conducting trials in Europe, knowing the CTA process is necessary.
Use professional pre-built templates to fill in and sign documents online faster. Get access to thousands of forms.
If you believe that this page should be taken down, please follow our DMCA take down process here.
This form is available in several versions. Select the version you need from the drop-down list below.